Logo Image
|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Partnerships: Bargaining Biotechs

Author(s)Kevin Gopal

Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.

Articles in this issue

over 25 years ago

Internet DTC - Minding Your P's & Q's

over 25 years ago

Regulation: Two-Track Plan

over 25 years ago

Policy: Tectonic Shift

over 25 years ago

Liberated?

over 25 years ago

A Matter of Taste

over 25 years ago

Pediatric Mandate

over 25 years ago

Genentech's Passion for Patients

over 25 years ago

Regulation: OK After All

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more